Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price target lifted by Argus from $42.00 to $50.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.
Several other equities research analysts have also commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $54.00 price target on shares of Teva Pharmaceutical Industries in a report on Tuesday. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the company an “overweight” rating in a report on Thursday, November 12th. Oppenheimer raised their target price on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. Finally, Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.64.
Check Out Our Latest Report on TEVA
Teva Pharmaceutical Industries Stock Down 8.8%
Shares of TEVA stock opened at $38.53 on Tuesday. Teva Pharmaceutical Industries has a fifty-two week low of $24.01 and a fifty-two week high of $44.57. The firm has a market capitalization of $44.90 billion, a PE ratio of 89.61, a P/E/G ratio of 3.66 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. The stock’s 50-day simple moving average is $40.56 and its 200-day simple moving average is $35.22.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The company had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter in the prior year, the company earned $0.78 EPS. Teva Pharmaceutical Industries’s quarterly revenue was down 1.9% on a year-over-year basis. Equities analysts expect that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.
Insider Activity at Teva Pharmaceutical Industries
In other news, EVP Richard Daniell sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $42.91, for a total value of $1,072,750.00. Following the completion of the sale, the executive vice president directly owned 55,755 shares in the company, valued at $2,392,447.05. The trade was a 30.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Sabag sold 46,000 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the transaction, the insider directly owned 80,760 shares in the company, valued at approximately $3,386,266.80. The trade was a 36.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 715,945 shares of company stock valued at $29,061,351 in the last ninety days. 0.54% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Root Financial Partners LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $33,000. Western Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $43,000. Sunbelt Securities Inc. acquired a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $45,000. CX Institutional acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $54,000. Finally, EverSource Wealth Advisors LLC raised its position in Teva Pharmaceutical Industries by 64.0% in the first quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock valued at $50,000 after purchasing an additional 647 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.
Recent Teva Pharmaceutical Industries Headlines
Investors following TEVA have been watching these headlines:
- Positive Sentiment: Barclays raised its price target to $50 from $47 and maintained an Overweight rating. Argus also raised its target to $50 and reaffirmed a Buy rating, while HC Wainwright maintained its Buy rating. Barclays analyst action Argus forecast HC Wainwright rating
- Neutral Sentiment: Teva said its R&D strategy, priorities and commitments remain unchanged, including its goal of $6–7 billion in innovative-medicines revenue by 2030. David Gardiner will lead the transition while the company searches for a permanent successor. Teva leadership announcement
- Negative Sentiment: Executive Vice President of Global R&D and Chief Medical Officer Eric Hughes is leaving for an opportunity outside Teva. His departure may unsettle investors given the importance of R&D execution to the company’s growth strategy, despite his planned support during the transition. R&D leadership transition report
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
Featured Articles
- Five stocks we like better than Teva Pharmaceutical Industries
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
